Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication.Methods: From claims re...

Full description

Bibliographic Details
Main Authors: Wen-Hsuan Tsai, Fung-Chang Sung, Lu-Ting Chiu, Ying-Hsiu Shih, Ming-Chieh Tsai, Shu-I Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Pharmacology
Subjects:
depression
anxiety
glucagon-like peptide-1 receptor agonist
diabetes
neuroendocrine
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/full

Similar Items